Table 2.
Summary of results and potential drug-drug interaction signals identified among oral anticoagulant users.
| Warfarin | Dabigatran | Rivaroxaban | Apixaban | Edoxaban | Pravastatin | |
|---|---|---|---|---|---|---|
| Number of precipitants identified | 736 | 424 | 519 | 424 | 38 | 638 |
| Number of precipitants with a RR estimate | 655 | 278 | 389 | 296 | 4 | 541 |
| Semi-Bayes adjusted RRs | ||||||
| Number of precipitants included | 626 | 256 | 374 | 280 | 4 | 493 |
| Range | 0.3–15.1 | 0.2–2.7 | 0.3–14.2 | 0.1–5.4 | 1.2–1.4 | 0.4–6.2 |
| Number of statistically significantly elevated semi-Bayes adjusted RR | 129 | 24 | 54 | 19 | 0 | 84 |
| Ratio of RRs | ||||||
| Number of precipitants examined | 493 | 249 | 360 | 273 | 4 | N/A |
| Range | 0.2–5.0 | 0.3–2.9 | 0.1–4.1 | 0.1–6.3 | 1.0–1.5 | N/A |
| Number of statistically significantly elevated ratio of RRs | 47 | 17 | 24 | 11 | 0 | N/A |
| Potential DDI signals * | 31 | 9 | 18 | 11 | 0 | N/A |
DDI – Drug-drug interactions, N/A – Not applicable, RR – Rate ratio.
*
Number of precipitants with statistically elevated ratio of RRs, excluding the ones not associated with statistically elevated RR among oral anticoagulant users, and associated with statistically reduced RR among pravastatin users.